Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10946863 | 0.82 | TDP1 (0.37) | TDP1MEN1POLBKMT2ATSHR | |
| SCHEMBL29207714 | 0.81 | ALDH1A1 (0.33) | TDP1 | |
| SCHEMBL25255150 | 0.81 | MEN1 (0.34) | TDP1MEN1KMT2ATSHR | |
| SCHEMBL1254697 | 0.77 | ALDH1A1 (0.38) | TDP1MEN1KMT2ATSHR | |
| SCHEMBL7682496 | 0.75 | — | — | |
| SCHEMBL1445552 | 0.74 | MEN1 (0.31) | TDP1MEN1KMT2A | |
| SCHEMBL30574208 | 0.72 | ALDH1A1 (0.43) | TDP1MEN1KMT2ATSHR | |
| SCHEMBL6331887 | 0.72 | ALDH1A1 (0.41) | MEN1KMT2A | |
| SCHEMBL25062278 | 0.72 | MEN1 (0.33) | TDP1MEN1KMT2ATSHR | |
| SCHEMBL6993496 | 0.72 | MEN1 (0.30) | TDP1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250049809-A1 | INHIBITORS OF MUTANT IDH1 AND IDH2 | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2025-02-13 | — | — | US | disclosed |
| EP-3010925-B1 | BACE INHIBITORS | LILLY CO ELI (US) | 2017-10-04 | — | — | EP | disclosed |
| EP-3010925-B1 | BACE INHIBITORS | LILLY CO ELI (US) | 2017-10-04 | — | — | EP | disclosed |
| WO-2017025565-A1 | 2-AMINO-7A-PHENYL-3,4,4A,5,7,7A-HEXAHYDROFURO[3,4-B]PYRIDINES AS BACE1 INHIBITORS | H. LUNDBECK A/S (DK) | 2017-02-16 | — | — | WO | disclosed |
| EP-2451793-B1 | BACE INHIBITORS | LILLY CO ELI (US) | 2016-11-02 | — | — | EP | disclosed |
| EP-2451793-B1 | BACE INHIBITORS | LILLY CO ELI (US) | 2016-11-02 | — | — | EP | disclosed |
| EP-3010925-A1 | BACE INHIBITORS | Eli Lilly & Company (US) | 2016-04-27 | — | — | EP | disclosed |
| CN-105324385-A | Bace inhibitors | LILLY CO ELI | 2016-02-10 | — | — | CN | disclosed |
| US-9169271-B2 | BACE inhibitors | ELI LILLY AND COMPANY (US) | 2015-10-27 | — | — | US | disclosed |
| US-9169271-B2 | BACE inhibitors | ELI LILLY AND COMPANY (US) | 2015-10-27 | — | — | US | disclosed |
| US-20120323001-A1 | BACE INHIBITORS | ELI LILLY AND COMPANY (US) | 2012-12-20 | — | — | US | disclosed |
| US-8278441-B2 | BACE inhibitors | ELI LILLY AND COMPANY (US) | 2012-10-02 | — | — | US | disclosed |
| US-8278441-B2 | BACE inhibitors | ELI LILLY AND COMPANY (US) | 2012-10-02 | — | — | US | disclosed |
| US-8278441-B2 | BACE inhibitors | ELI LILLY AND COMPANY (US) | 2012-10-02 | — | — | US | disclosed |
| EP-2451793-A1 | BACE INHIBITORS | Eli Lilly and Company (US) | 2012-05-16 | — | — | EP | disclosed |
| US-20110009395-A1 | BACE INHIBITORS | ELI LILLY AND COMPANY (US) | 2011-01-13 | — | — | US | disclosed |
| US-20110009395-A1 | BACE INHIBITORS | ELI LILLY AND COMPANY (US) | 2011-01-13 | — | — | US | disclosed |
| US-20110009395-A1 | BACE INHIBITORS | ELI LILLY AND COMPANY (US) | 2011-01-13 | — | — | US | disclosed |
| WO-2011005738-A1 | BACE INHIBITORS | ELI LILLY AND COMPANY (US) | 2011-01-13 | — | — | WO | disclosed |
| WO-2011005738-A1 | BACE INHIBITORS | ELI LILLY AND COMPANY (US) | 2011-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120323001-A1 | BACE INHIBITORS | BACE1, BACE2, APP | TDP1 279/4885MEN1 2551/4885POLB 349/4885 |
| US-20110009395-A1 | BACE INHIBITORS | BACE1, BACE2, APP | TDP1 279/4885MEN1 2551/4885POLB 349/4885 |
| US-20250049809-A1 | INHIBITORS OF MUTANT IDH1 AND IDH2 | IDH1, IDH2, IDH3A | TDP1 577/4885MEN1 1432/4885POLB 2177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.